Both αCD137/IL-2-Fc and Lipo-αCD137/Lipo-IL-2-Fc treatment induced substantial CD8+ T-cell and NK cell tumor infiltrates (to comparable levels) and increased intratumoral CD8+/Treg ratios approximately fivefold (Fig. 7b–d). The gene discussed is CD8A; the disease is neoplasm.